查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2069614

前列腺癌生物標記市場：按類型、應用、最終用途、國家和公司分類的分析（2026-2034 年）

Prostate Cancer Biomarkers Market Report by Type, Application, End Use, Countries and Companies Analysis 2026-2034
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

前列腺癌生物標記市場規模及預測（2026-2034）

預計到2034年，前列腺癌生物標記市場規模將達到158.1億美元，高於2025年的54.7億美元，2026年至2034年的複合年成長率為12.52%。前列腺癌生物標記市場擴張的原因包括：前列腺癌發病率上升、精準醫療的普及、對非侵入性診斷測試的需求不斷成長，以及基因組和分子生物標記技術的持續進步，這些進步改善了早期檢測、治療方法選擇和患者後續觀察。

前列腺癌生物標記市場概覽

前列腺癌生物標記是存在於血液、尿液、組織和其他體液中的生物分子，可用於檢測、診斷、後續觀察和預測前列腺癌的進展。常見的生物標記包括前列腺特異性抗原 (PSA)、PCA3、TMPRSS2-ERG 基因融合、循環性腫瘤細胞和基因組特徵。這些生物標記提供有關腫瘤行為、疾病侵襲性和治療反應的重要資訊。醫療專業人員利用生物標記檢測來支持早期診斷、減少不必要的切片檢查、指南個人化治療決策以及監測治療後的復發情況。分子診斷和基因組學的進步提高了生物標記的準確性，使得全球範圍內對前列腺癌的治療更加精準有效。

由於全球前列腺癌負擔日益加重、人們對早期檢測的認知不斷提高以及個人化醫療的日益普及，前列腺癌生物標記市場正經歷著顯著成長。基於生物標記的檢測能夠進行精準的風險分層，並透過輔助臨床決策減少不必要的侵入性手術。液態生物檢體、基因組分析和分子診斷等技術的進步進一步提高了診斷的準確性。醫療系統正在加大對癌症篩檢計畫的投入，而製藥公司則在標靶治療的研發中充分利用生物標記。此外，法規核准的進展和研究合作的拓展正在加速創新生物標記解決方案在已開發國家和新興市場醫療市場的商業化進程。

前列腺癌生物標記市場最新趨勢

  • 2026年6月，Foundation Medicine宣布，FoundationOne® Liquid CDx和FoundationOne® CDx已獲得美國食品藥物管理局（ FDA）批准，作為伴隨診斷試劑，用於識別攜帶同源重組修復（HRR）基因突變且適合接受TALZENNA®和XTANDI®聯合治療的轉移性轉移性去勢抗性前列腺癌患者。此次批准拓展了基因生物標記在指導進行性前列腺癌患者標靶治療選擇方面的臨床效用。
  • 2026年5月，Tempus AI推出了針對轉移性荷爾蒙敏感性前列腺癌患者的ArteraAI前列腺檢測（mHSPC）。這項由人工智慧驅動的數位病理檢測結合了臨床和組織病理學數據，為每位患者產生個人化的死亡風險預測，從而輔助確定治療強度。此次發布標誌著生物標記主導的精準腫瘤學和數位病理學在前列腺癌治療領域的應用取得了重大進展。
  • 2024年3月，Tempus AI宣布推出p-MSI臨床版，這是一款基於人工智慧的前列腺癌生物標記演算法。此方案與公司xT基因組分析檢測技術結合，利用數位病理影像辨識可能攜帶微衛星不穩定性高（MSI-H）腫瘤的患者。 MSI-H腫瘤是一種生物標記物，提示患者可能對免疫療法有反應。此次發布拓展了人工智慧在基於生物標記的前列腺癌治療方法選擇中的應用。

前列腺癌生物標記市場的成長要素

全球前列腺癌負擔日益加重，推動了對早期檢測的需求。

全球前列腺癌發生率的不斷上升，使得對能夠實現更早期、更精準診斷的先進生物標記技術的需求日益成長。人口老化、公眾意識的提高以及癌症篩檢計畫的擴展，都導致需要進行診斷評估的患者數量不斷增加。生物標記能夠幫助臨床醫生識別具有臨床意義的癌症，同時最大限度地減少不必要的切片檢查和過度治療。醫療機構正擴大採用分子檢測工具來改善風險分層，並支持實證治療方案的發展。此外，公共和私人對癌症研究的投資正在加速下一代生物標記平台的開發。隨著醫療系統致力於透過早期療育提高生存率，預計已開發市場和新興市場對創新前列腺癌生物標記的需求將持續成長。

2025年4月，Veracyte宣布推出Decipher前列腺轉移基因組分類器，進一步拓展其基因生物標記產品組合，以支持轉移性前列腺癌患者的治療決策。該檢測在全面商業化之前透過早期試用計畫推出，增強了進行性前列腺癌精準腫瘤學的治療能力。

精準醫療和基因組分析的廣泛應用

精準醫療在癌症治療中的日益普及是前列腺癌生物標記市場的主要驅動力。醫生擴大利用基因組和分子生物標記來識別疾病的侵襲性、預測治療反應並選擇個人化治療方案。以生物標記為基礎的醫療方法在提高治療效果的同時，也能減少不必要的介入。定序技術、計算生物學和人工智慧的進步正在提高生物標記檢測的預測準確性。製藥公司也在臨床試驗中採用基於生物標記的患者選擇方法，以改善藥物研發的成果。隨著醫療機構對更個人化的治療方案的需求不斷成長，醫院、癌症中心和專業診斷實驗室對先進基因組檢測解決方案的需求也持續成長。

2026年5月，Myriad Genetics公司推出了Prolaris®+AI，這是第一個將基因組風險評估與人工智慧驅動的數位病理學相結合的前列腺癌篩檢解決方案。該解決方案整合了分子和病理數據，為制定個人化的主動後續觀察和治療方案提供了支持。

液態生物檢體和非侵入性診斷技術的進展

液態生物檢體和非侵入性診斷技術的進步正顯著加速市場成長。傳統的組織切片檢查具有侵入性，且難以重複，而液態生物檢體技術則可從血液和尿液檢體中獲取分子資訊。這些方法減輕了患者的負擔，並有助於在整個治療過程中進行持續的疾病監測。檢測循環腫瘤DNA、RNA和表觀遺傳生物標記的敏感度不斷提高，增強了臨床對非侵入性診斷方法的信心。此外，醫療專業人員擴大利用液態生物檢體來評估治療反應並識別新的抗藥性機制。預計未來幾年，對微創診斷日益成長的需求將推動先進生物標記平台的廣泛應用。

2026年4月，Precede Biosciences基因表現Precede Bio Insight™，這是一個全基因組液態生物檢體平台，能夠利用少量血漿樣本評估基因表現、訊號路徑活性和腫瘤生物學特徵。該公司展示了相關數據，證明該平台可應用於多種癌症類型，包括前列腺癌，凸顯了基於液態生物檢體的生物標記技術日益成長的重要性。

前列腺癌生物標記市場面臨的挑戰

新興生物標記特異性低且缺乏臨床有效性

儘管已取得顯著進展，但許多前列腺癌生物標記仍面臨臨床檢驗和診斷特異性方面的挑戰。一些生物標記可能產生假陽性或假陰性結果，從而影響醫生的信心和臨床應用。要使生物標記成為標準的臨床工具，通常需要進行大規模的檢驗研究。患者族群、調查方法和檢查室操作流程的差異也會進一步影響檢測效能。監管機構在批准前也要求提供充分的安全性、有效性和臨床效用證據。這些因素增加了研發時間和商業化成本，阻礙了新型生物標記技術快速應用於常規臨床實踐。

先進分子診斷測試高成本

基因組分析、次世代定序和先進分子診斷平台的高成本仍然是市場上的重大挑戰。許多醫療機構，尤其是在中低收入國家，由於預算限制，無法提供先進的生物標記檢測服務。此外，不同地區對新型生物標記檢測的保險報銷政策差異很大，為醫療服務提供者和生產商帶來了不確定性。檢查室基礎設施不足和訓練有素的分子病理學專家短缺也會進一步阻礙這些檢測技術的普及。因此，儘管先進的前列腺癌生物標記檢測具有重要的臨床價值，但全球仍有相當一部分患者可能無法獲得這些檢測服務。

美國前列腺癌生物標記市場

美國憑藉其先進的分子診斷基礎設施、健全的保險報銷體係以及精準腫瘤學的廣泛應用，在前列腺癌生物標記市場中佔最大佔有率。生物標記檢測正日益廣泛地應用於風險分層、治療方法選擇和疾病後續觀察。前列腺癌發生率的不斷上升進一步推動了對基因組分類、液態生物檢體活體組織切片和伴隨診斷的需求。生技公司、學術機構和癌症中心之間的研究合作正持續加速創新。

根據美國國家癌症研究所（SEER計畫）的估計，到2026年，美國將新增333,830例前列腺癌病例，並有36,320人死於前列腺癌，前列腺癌將占美國所有新診斷癌症病例的15.8%。患者數量的增加推動了對先進生物標記解決方案的需求。

德國前列腺癌生物標記市場

德國憑藉其先進的醫療基礎設施、強大的腫瘤研究能力以及精準醫療的廣泛應用，已成為歐洲前列腺癌生物標記的主要市場之一。醫院和癌症中心正擴大利用基因組檢測、分子診斷和基於生物標記的風險評估工具來改善臨床決策和患者預後。對癌症早期檢測和個人化治療策略的日益重視進一步推動了市場成長。此外，優惠的保險報銷政策和對癌症研究的持續投入也促進了創新生物標記技術的商業化。

根據德國癌症登記中心（ZfKD）的數據，2023年德國報告了79,610例新增前列腺癌病例，年齡調整後的發生率為每10萬人114.7例，前列腺癌相關死亡人數為15,196人。如此高的疾病負擔持續推動著對基於生物標記的先進診斷和監測解決方案的巨大需求。

中國前列腺癌生物標記市場

受醫療衛生快速現代化、老齡人口不斷成長以及精準醫療投入增加的推動，中國正迅速崛起為全球成長最快的前列腺癌生物標記市場之一。政府推行的癌症篩檢和早期診斷舉措，促進了先進分子診斷技術的應用。國內生技公司正積極研發基因組檢測和液態生物檢體平台，創造了巨大的成長機會。醫療支出不斷增加以及腫瘤專科服務的普及，進一步推動了市場擴張。

根據國際癌症研究機構（IARC）的預測，全球前列腺癌發病率預計將顯著上升，而人口眾多且老化的中國預計將成為這一成長的主要貢獻者。 IARC預測，到2040年，全球前列腺癌確診病例將接近每年300萬例，並強調包括中國在內的主要國家需要加強診斷能力。

沙烏地阿拉伯前列腺癌生物標記市場

在沙烏地阿拉伯，前列腺癌生物標記市場正穩步擴張，這主要得益於醫療保健投資的增加、人們對癌症早期檢測意識的提高，以及政府基於「2030願景」的醫療保健轉型舉措。各大癌症治療中心正日益採用精準醫療、基因組檢測和先進的分子診斷技術。檢測基礎設施的擴建和個人化治療方案的整合進一步推動了市場成長。不斷成長的醫療保健支出以及與國際診斷公司的合作也加速了創新生物標記技術的普及。

前列腺癌基因生物標記市場

前列腺癌基因生物標記細分市場是整個前列腺癌生物標記市場中成長最快的領域之一。包括BRCA1、BRCA2、ATM、CHEK2、HOXB13和其他基因組突變在內的基因生物標記正被擴大用於評估遺傳性癌症風險、預測疾病侵襲性以及指南標靶治療的選擇。次世代定序（NGS）和精準腫瘤學方法的日益普及正在加速對基因生物標記檢測的需求。醫療服務提供者正在利用這些生物標記來識別可能受益於PARP抑制劑和其他標靶治療的患者。此外，人們對遺傳性癌症症候群的認知不斷提高，以及推薦細胞株和體細胞檢測的臨床指南的擴展，也推動了市場成長。基因組技術的持續進步可望進一步拓展臨床應用和市場機會。

前列腺癌診斷與風險分層市場

前列腺癌的診斷和風險分層在早期發現和最佳化前列腺癌患者的治療方案製定方面發揮著至關重要的作用。診斷生物標記和基因組分類檢測，例如PSA、PCA3和TMPRSS2-ERG，有助於醫生區分進展緩慢和高度侵襲性疾病，從而減少不必要的切片檢查和過度治療。前列腺癌發生率的上升以及對個人化醫療日益重視，推動了對先進風險分層工具的需求。醫療機構擴大採用結合分子生物標記、影像技術和人工智慧（AI）分析的多方面診斷方法，以提高臨床準確性。此外，非侵入性檢測和基因組分析解決方案的日益普及也改善了病患管理。預計這些因素將顯著促進該細分市場的擴張。

醫院和診斷檢查室市場

醫院和診斷檢查室是前列腺癌生物標記市場最大的終端使用者群體，在癌症診斷、預後評估和治療進展監測中發揮核心作用。這些機構進行多種生物標記檢測，包括PSA篩檢、基因組分析、液態生物檢體分析和分子診斷評估。隨著精準醫療的日益普及，醫院和檢查室正積極投資先進的定序平台和生物標記檢測能力。大規模醫療機構正在將基於生物標記的決策融入常規腫瘤診療實踐中，以改善患者預後並最佳化治療方法方案。此外，前列腺癌篩檢率的提高、實驗室基礎設施的擴建以及對個人化癌症治療需求的不斷成長，都推動了檢測量的成長。預計持續的技術進步將進一步鞏固該領域的市場地位。

前列腺癌生物標記市場細分

類型

  • 基因生物標記
  • 基於細胞的生物標記
  • 代謝體學物標誌物

目的

  • 篩檢和早期檢測
  • 診斷和風險分層
  • 監測預後和治療進展
  • 伴隨診斷

最終用途

  • 醫院和診斷檢查室
  • 學術和研究機構
  • 生物製藥公司

國家

北美洲

  • 美國
  • 加拿大

歐洲

  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 比利時
  • 荷蘭
  • 土耳其

亞太地區

  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 泰國
  • 馬來西亞
  • 印尼
  • 紐西蘭

拉丁美洲

  • 巴西
  • 墨西哥
  • 阿根廷

中東和非洲

  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

所有主要參與企業均從五個角度進行分析。

  • 概述
  • 主要角色
  • 近期趨勢
  • SWOT分析
  • 收入分析

主要公司分析

  • Exact Sciences Corp
  • Myriad Genetics Inc
  • BIO-TECHNE Corp
  • OPKO HEALTH, INC.
  • MDxHealth SA
  • Veracyte Inc
  • Roche Diagnostic Ltd.
  • Pfizer Inc.

目錄

第1章：引言

第2章：調查方法

第3章摘要整理

第4章 市場動態

  • 成長的驅動力
  • 任務

第5章：前列腺癌生物標記市場

第6章：前列腺癌生物標記市場佔有率分析

  • 按類型
  • 用途別
  • 按最終用途
  • 國家

第7章 類型－過去與現在的市場趨勢及預測

  • 基因生物標記
  • 基於細胞的生物標記
  • 代謝體學物標誌物

第8章 應用－過去與現在的市場趨勢及預測

  • 篩檢和早期檢測
  • 診斷和風險分層
  • 預後和治療監測
  • 伴隨診斷

第9章 最終用途－過去與現在的市場趨勢及預測

  • 醫院和診斷檢測實驗室
  • 學術和研究機構
  • 生物製藥公司

第10章：各國－過去與現在的市場趨勢及預測

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 比利時
    • 荷蘭
    • 土耳其
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 泰國
    • 馬來西亞
    • 印尼
    • 澳洲
    • 紐西蘭
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第11章：波特五力模型分析

第12章 SWOT 分析

第13章 併購

第14章：主要參與企業分析

  • Exact Sciences Corp
  • Myriad Genetics Inc
  • BIO-TECHNE Corp
  • OPKO HEALTH,INC.
  • MDxHealth SA
  • Veracyte Inc
  • Roche Diagnostic Ltd.
  • Pfizer Inc.
簡介目錄

Prostate Cancer Biomarkers Market Size and Forecast 2026-2034

Prostate Cancer Biomarkers Market is expected to reach US$ 15.81 Billion by 2034 from US$ 5.47 Billion in 2025, with a CAGR of 12.52% from 2026 to 2034. The prostate cancer biomarkers market is expanding due to rising prostate cancer prevalence, increasing adoption of precision medicine, growing demand for non-invasive diagnostic tests, and continuous advancements in genomic and molecular biomarker technologies that improve early detection, treatment selection, and patient monitoring.

Prostate Cancer Biomarkers Industry Overview

Prostate cancer biomarkers are biological molecules found in blood, urine, tissue, or other body fluids that help detect, diagnose, monitor, and predict the progression of prostate cancer. Common biomarkers include prostate-specific antigen (PSA), PCA3, TMPRSS2-ERG gene fusion, circulating tumor cells, and genomic signatures. These biomarkers provide valuable information about tumor behavior, disease aggressiveness, and treatment response. Healthcare providers use biomarker testing to support early diagnosis, reduce unnecessary biopsies, guide personalized treatment decisions, and monitor recurrence after therapy. Advances in molecular diagnostics and genomics are improving biomarker accuracy, enabling more targeted and effective prostate cancer management worldwide.

The prostate cancer biomarkers market is witnessing significant growth due to the increasing global burden of prostate cancer, rising awareness regarding early disease detection, and the growing adoption of personalized medicine. Biomarker-based testing enables accurate risk stratification and supports clinical decision-making, reducing unnecessary invasive procedures. Technological advancements in liquid biopsy, genomic profiling, and molecular diagnostics are further enhancing diagnostic precision. Healthcare systems are increasingly investing in cancer screening programs, while pharmaceutical companies are utilizing biomarkers for targeted therapy development. Additionally, favorable regulatory approvals and expanding research collaborations are accelerating the commercialization of innovative biomarker solutions across developed and emerging healthcare markets.

Recent Developments in Prostate Cancer Biomarkers Market

  • In June 2026, Foundation Medicine announced U.S. FDA approval of FoundationOne(R) Liquid CDx and FoundationOne(R) CDx as companion diagnostics for identifying patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer eligible for TALZENNA(R) plus XTANDI(R) treatment. The approval expanded the clinical utility of genomic biomarkers in guiding targeted therapy selection for advanced prostate cancer patients.
  • In May 2026, Tempus AI launched the ArteraAI Prostate Test (mHSPC) for patients with metastatic hormone-sensitive prostate cancer. The AI-powered digital pathology test combines clinical and histopathological data to generate individualized mortality risk predictions and support therapy-intensity decisions. The launch represents a significant advancement in biomarker-driven precision oncology and digital pathology applications in prostate cancer care.
  • In March 2024, Tempus AI announced the clinical launch of p-MSI, an AI-driven biomarker algorithm for prostate cancer patients. The solution is integrated with the company's xT genomic profiling assay and uses digital pathology images to identify patients who may have microsatellite instability-high (MSI-H) tumors, a biomarker associated with potential response to immunotherapy. The launch expanded the application of artificial intelligence in biomarker-guided prostate cancer treatment selection.

Growth Drivers for the Prostate Cancer Biomarkers Market

Rising Global Burden of Prostate Cancer Driving Demand for Early Detection

The increasing prevalence of prostate cancer worldwide is creating strong demand for advanced biomarker technologies that enable earlier and more accurate diagnosis. Aging populations, improved awareness campaigns, and expanding cancer screening programs are contributing to a growing number of patients requiring diagnostic evaluation. Biomarkers help clinicians identify clinically significant cancers while minimizing unnecessary biopsies and overtreatment. Healthcare providers are increasingly adopting molecular testing tools that improve risk stratification and support evidence-based treatment planning. Furthermore, public and private investments in oncology research are accelerating the development of next-generation biomarker platforms. As healthcare systems focus on improving survival outcomes through earlier intervention, demand for innovative prostate cancer biomarkers is expected to continue rising across both developed and emerging markets.

In April 2025, Veracyte announced the launch of the Decipher Prostate Metastatic Genomic Classifier, expanding its genomic biomarker portfolio to support treatment decision-making for patients with metastatic prostate cancer. The test was introduced through an early-access program before broader commercialization, strengthening precision oncology capabilities in advanced prostate cancer management.

Growing Adoption of Precision Medicine and Genomic Profiling

The increasing integration of precision medicine into oncology practice is a major driver of the prostate cancer biomarkers market. Physicians are increasingly using genomic and molecular biomarkers to identify disease aggressiveness, predict treatment response, and select personalized therapies. Biomarker-guided care improves treatment effectiveness while reducing exposure to unnecessary interventions. Advances in sequencing technologies, computational biology, and artificial intelligence are enhancing the predictive power of biomarker tests. Pharmaceutical companies are also incorporating biomarker-based patient selection into clinical trials to improve drug development outcomes. As healthcare providers seek more individualized treatment approaches, demand for sophisticated genomic testing solutions continues to expand across hospitals, cancer centers, and specialized diagnostic laboratories.

In May 2026, Myriad Genetics launched Prolaris(R) + AI, the first prostate cancer test to combine genomic risk assessment with artificial intelligence-powered digital pathology. The solution integrates molecular and pathological data to support personalized active-surveillance decisions and treatment planning.

Advancements in Liquid Biopsy and Non-Invasive Diagnostic Technologies

Technological progress in liquid biopsy and non-invasive testing is significantly accelerating market growth. Traditional tissue biopsies can be invasive and difficult to repeat, whereas liquid biopsy technologies provide molecular information through blood or urine samples. These approaches improve patient comfort and facilitate continuous disease monitoring throughout the treatment journey. Enhanced sensitivity in detecting circulating tumor DNA, RNA, and epigenetic biomarkers is improving clinical confidence in non-invasive testing methods. In addition, healthcare providers are increasingly utilizing liquid biopsies to assess treatment response and identify emerging resistance mechanisms. The growing preference for minimally invasive diagnostics is expected to drive substantial adoption of advanced biomarker platforms over the coming years.

In April 2026, Precede Biosciences announced the launch of Precede Bio Insight(TM), a genome-wide liquid biopsy platform capable of inferring gene expression, pathway activity, and tumor biology from a small plasma sample. The company presented data demonstrating applications across multiple cancers, including prostate cancer, highlighting the growing importance of liquid biopsy-based biomarker technologies.

Challenges in the Prostate Cancer Biomarkers Market

Limited Specificity and Clinical Validation of Emerging Biomarkers

Despite significant advancements, many prostate cancer biomarkers face challenges related to clinical validation and diagnostic specificity. Some biomarkers may generate false-positive or false-negative results, affecting physician confidence and clinical adoption. Large-scale validation studies are often required before biomarkers can become standard clinical tools. Variations in patient populations, testing methodologies, and laboratory procedures may further influence test performance. Regulatory agencies also require extensive evidence regarding safety, efficacy, and clinical utility before granting approval. These factors increase development timelines and commercialization costs, limiting the rapid introduction of novel biomarker technologies into routine clinical practice.

High Cost of Advanced Molecular Diagnostic Testing

The high cost associated with genomic profiling, next-generation sequencing, and advanced molecular diagnostic platforms remains a significant market challenge. Many healthcare facilities, particularly in low- and middle-income countries, face budget constraints that limit access to sophisticated biomarker testing services. Reimbursement policies for novel biomarker assays also vary considerably across regions, creating uncertainty for providers and manufacturers. Inadequate laboratory infrastructure and shortages of trained molecular pathology professionals can further hinder adoption. Consequently, despite their clinical benefits, advanced prostate cancer biomarker tests may remain inaccessible to a substantial portion of the global patient population.

United States Prostate Cancer Biomarkers Market

The United States represents the largest prostate cancer biomarkers market due to advanced molecular diagnostic infrastructure, strong reimbursement systems, and widespread adoption of precision oncology. Biomarker testing is increasingly used to support risk stratification, treatment selection, and disease monitoring. The growing incidence of prostate cancer is further driving demand for genomic classifiers, liquid biopsy assays, and companion diagnostics. Research collaborations among biotechnology companies, academic institutions, and cancer centers continue to accelerate innovation.

According to the U.S. National Cancer Institute (SEER Program), an estimated 333,830 new prostate cancer cases and 36,320 deaths are expected in 2026, with prostate cancer accounting for 15.8% of all newly diagnosed cancers in the country. This increasing patient pool is strengthening demand for advanced biomarker solutions.

Germany Prostate Cancer Biomarkers Market

Germany is one of the leading markets for prostate cancer biomarkers in Europe, supported by advanced healthcare infrastructure, strong oncology research capabilities, and increasing adoption of precision medicine. Hospitals and cancer centers are increasingly utilizing genomic testing, molecular diagnostics, and biomarker-based risk assessment tools to improve clinical decision-making and patient outcomes. The growing emphasis on early cancer detection and personalized treatment strategies is further driving market growth. In addition, favorable reimbursement policies and continuous investments in cancer research support the commercialization of innovative biomarker technologies.

According to Zentrum fur Krebsregisterdaten (ZfKD), Germany reported 79,610 new prostate cancer cases in 2023, with an age-standardized incidence rate of 114.7 per 100,000 population and 15,196 prostate cancer-related deaths. The high disease burden continues to generate substantial demand for advanced biomarker-based diagnostics and monitoring solutions.

China Prostate Cancer Biomarkers Market

China is emerging as one of the fastest-growing prostate cancer biomarkers markets due to rapid healthcare modernization, an expanding elderly population, and increasing investments in precision medicine. Government initiatives promoting cancer screening and early diagnosis are encouraging adoption of advanced molecular diagnostic technologies. Domestic biotechnology companies are actively developing genomic testing and liquid biopsy platforms, creating significant growth opportunities. Rising healthcare spending and broader access to specialized oncology services are further supporting market expansion.

According to the International Agency for Research on Cancer (IARC), global prostate cancer incidence is expected to rise substantially, with China contributing significantly because of its large and aging population. IARC projects worldwide prostate cancer diagnoses could approach 3 million cases annually by 2040, highlighting the need for enhanced diagnostic capabilities across major countries including China.

Saudi Arabia Prostate Cancer Biomarkers Market

Saudi Arabia's prostate cancer biomarkers market is expanding steadily due to increasing healthcare investments, growing awareness of early cancer detection, and the government's Vision 2030 healthcare transformation initiatives. The adoption of precision medicine, genomic testing, and advanced molecular diagnostics is increasing across major oncology centers. Expanding laboratory infrastructure and the integration of personalized treatment approaches are further supporting market growth. Rising healthcare expenditure and collaborations with international diagnostic companies are also accelerating access to innovative biomarker technologies.

Prostate Cancer Genetic Biomarker Market

The Prostate Cancer Genetic Biomarker segment represents a rapidly growing area within the broader prostate cancer biomarkers market. Genetic biomarkers, including BRCA1, BRCA2, ATM, CHEK2, HOXB13, and other genomic alterations, are increasingly used to assess inherited cancer risk, predict disease aggressiveness, and guide targeted treatment selection. The growing adoption of next-generation sequencing (NGS) and precision oncology approaches is accelerating demand for genetic biomarker testing. Healthcare providers are utilizing these biomarkers to identify patients who may benefit from PARP inhibitors and other targeted therapies. Additionally, increasing awareness of hereditary cancer syndromes and expanding clinical guidelines recommending germline and somatic testing are supporting market growth. Continuous advancements in genomic technologies are expected to further expand clinical applications and market opportunities.

Prostate Cancer Diagnostic and Risk Stratification Market

The Prostate Cancer Diagnostic and Risk Stratification segment plays a critical role in improving early detection and treatment planning for prostate cancer patients. Diagnostic biomarkers such as PSA, PCA3, TMPRSS2-ERG, and genomic classifier tests help physicians distinguish between indolent and aggressive disease, reducing unnecessary biopsies and overtreatment. Rising prostate cancer incidence and increasing emphasis on personalized medicine are driving demand for advanced risk stratification tools. Healthcare providers are increasingly adopting multi-parametric diagnostic approaches that combine molecular biomarkers, imaging technologies, and artificial intelligence-based analytics to improve clinical accuracy. Furthermore, the growing availability of non-invasive testing methods and genomic profiling solutions is enhancing patient management. These factors are expected to contribute significantly to the expansion of this market segment.

Hospitals & Diagnostic Laboratories Market

Hospitals and diagnostic laboratories constitute the largest end-user segment in the prostate cancer biomarkers market due to their central role in cancer diagnosis, prognosis, and treatment monitoring. These facilities perform a wide range of biomarker tests, including PSA screening, genomic profiling, liquid biopsy analysis, and molecular diagnostic assessments. The increasing adoption of precision medicine is encouraging hospitals and laboratories to invest in advanced sequencing platforms and biomarker testing capabilities. Large healthcare institutions are integrating biomarker-based decision-making into routine oncology practice to improve patient outcomes and optimize treatment selection. Additionally, rising prostate cancer screening rates, expanding laboratory infrastructure, and growing demand for personalized cancer care are driving testing volumes. Continuous technological advancements are expected to further strengthen this segment's market position.

Prostate Cancer Biomarkers Market Segments

Type

  • Genetic Biomarker
  • Cell-based Biomarkers
  • Metabolomic Biomarkers

Application

  • Screening And Early Detection
  • Diagnostic And Risk Stratification
  • Prognosis And Treatment Monitoring
  • Companion Diagnostics

End Use

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Biopharmaceutical Companies

Countries

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • United Arab Emirates

All the Key players have been covered with 5 Viewpoints

  • Overviews
  • Key Person
  • Recent Developments
  • SWOT Analysis
  • Revenue Analysis

Key Players Analysis

  • Exact Sciences Corp
  • Myriad Genetics Inc
  • BIO-TECHNE Corp
  • OPKO HEALTH, INC.
  • MDxHealth SA
  • Veracyte Inc
  • Roche Diagnostic Ltd.
  • Pfizer Inc.

Table of Contents

1. Introduction

2. Research Methodology

  • 2.1 Data Source
    • 2.1.1 Primary Sources
    • 2.1.2 Secondary Sources
  • 2.2 Research Approach
    • 2.2.1 Top-Down Approach
    • 2.2.2 Bottom-Up Approach
  • 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Prostate Cancer Biomarkers Market

6. Prostate Cancer Biomarkers Market Share Analysis

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By End Use
  • 6.4 By Countries

7. Type - Historical and Current Market Trends & Forecast

  • 7.1 Genetic Biomarker
  • 7.2 Cell-based Biomarkers
  • 7.3 Metabolomic Biomarkers

8. Application - Historical and Current Market Trends & Forecast

  • 8.1 Screening And Early Detection
  • 8.2 Diagnostic And Risk Stratification
  • 8.3 Prognosis And Treatment Monitoring
  • 8.4 Companion Diagnostics

9. End Use - Historical and Current Market Trends & Forecast

  • 9.1 Hospitals & Diagnostic Laboratories
  • 9.2 Academic & Research Institues
  • 9.3 Biopharmaceutical Companies

10. Countries - Historical and Current Market Trends & Forecast

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Merger and Acquisition

14. Key Players Analysis

  • 14.1 Exact Sciences Corp
    • 14.1.1 Overviews
    • 14.1.2 Key Person
    • 14.1.3 Recent Developments
    • 14.1.4 SWOT Analysis
    • 14.1.5 Revenue Analysis
  • 14.2 Myriad Genetics Inc
    • 14.2.1 Overviews
    • 14.2.2 Key Person
    • 14.2.3 Recent Developments
    • 14.2.4 SWOT Analysis
    • 14.2.5 Revenue Analysis
  • 14.3 BIO-TECHNE Corp
    • 14.3.1 Overviews
    • 14.3.2 Key Person
    • 14.3.3 Recent Developments
    • 14.3.4 SWOT Analysis
    • 14.3.5 Revenue Analysis
  • 14.4 OPKO HEALTH,INC.
    • 14.4.1 Overviews
    • 14.4.2 Key Person
    • 14.4.3 Recent Developments
    • 14.4.4 SWOT Analysis
    • 14.4.5 Revenue Analysis
  • 14.5 MDxHealth SA
    • 14.5.1 Overviews
    • 14.5.2 Key Person
    • 14.5.3 Recent Developments
    • 14.5.4 SWOT Analysis
    • 14.5.5 Revenue Analysis
  • 14.6 Veracyte Inc
    • 14.6.1 Overviews
    • 14.6.2 Key Person
    • 14.6.3 Recent Developments
    • 14.6.4 SWOT Analysis
    • 14.6.5 Revenue Analysis
  • 14.7 Roche Diagnostic Ltd.
    • 14.7.1 Overviews
    • 14.7.2 Key Person
    • 14.7.3 Recent Developments
    • 14.7.4 SWOT Analysis
    • 14.7.4 Revenue Analysis
  • 14.8 Pfizer Inc.
    • 14.8.1 Overviews
    • 14.8.2 Key Person
    • 14.8.3 Recent Developments
    • 14.8.4 SWOT Analysis
    • 14.8.5 Revenue Analysis